Open AccessAdenoviral Therapy in Radioresistant Squamous Cell Cancer
Author(s) -
Lee SeiYoung,
Kim SeHeon
Publication year - 2011
Publication title -
otolaryngology–head and neck surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.232
H-Index - 121
eISSN - 1097-6817
pISSN - 0194-5998
DOI - 10.1177/0194599811416318a60
Subject(s) - radioresistance , oncolytic virus , cell culture , cancer research , oncolytic adenovirus , cytotoxic t cell , cell , cancer , biology , immunohistochemistry , medicine , immunology , in vitro , tumor cells , biochemistry , genetics
Objective Resistance to radiation is one of the main determinants of treatment outcome in the oral squamous cell carcinoma. We aim to identify that genetically modified adenovirus expressing RLX (Relaxin), which affects collagen metabolism, can effectively inhibit growth of the radioresistant oral SCC cell line. Method Radioresistant oral SCC cell line was established. LDH assay was used to confirm the acquisition of radioresistance and cytotoxic effect of adenovirus. Tumor bearing nude mice were treated with expressing RLX adenovirus, dose dependently. Spread of adenovirus throughout the tumor mass was verified by immunohistochemistry. Results Radioresistant oral SCC cell line was more resistant to radiation therapy than mother oral SCC cell lines (p3 vs 45mm 3 vs 0mm 3 at Day 21). Also, the data shown that the minimum dose of adenovirus has the ability to kill the tumor cells (MOI = 5). In IHC data, the RLX expressing adenovirus eliminated collagens more effectively than non‐RLX expressing adenovirus. Conclusion Oncolytic adenovirus can effectively inhibit growth of the radioresistance oral cancer cell line.